Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisioning
Related news for (ACON)
- Spider Silk, Spines, and Satoshi — Innovation Headlines Today’s Movers
- Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
- 24/7 Market News Snapshot 13 October, 2025 – Aclarion, Inc. Common Stock (NASDAQ:ACON)
- Today’s Top Performers: MoBot’s Market Review 10/13/25 04:00 AM
- MoBot’s Stock Market Highlights – 10/10/25 04:00 PM